Full Press Release Details
NLS Pharmaceutics Ltd. Regains Full Compliance
with Nasdaq Listing Requirements
ZURICH, SWITZERLAND / ACCESSWIRE / October 28,
2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical
company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders,
today announced that it has received notice from the Nasdaq Stock Market LLC ("NASDAQ") informing the Company that it has
regained full compliance with the bid price requirement in Listing Rule 5550(a)(2) and the equity requirement in Listing Rule 5550(b)(1).
"We are pleased to report that Nasdaq has
recognized our full compliance with their listing requirements," said Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics.
"Their confirmation follows our successful efforts to improve our balance sheet, including raising new capital and implementing
a reverse share split."
NLS is a global development-stage biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development
of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered
in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing
product candidates. For more information, please visit www.nlspharma.com.
Investor Relations Contact